ID

34401

Descripción

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib; ODM derived from: https://clinicaltrials.gov/show/NCT01514448

Link

https://clinicaltrials.gov/show/NCT01514448

Palabras clave

  1. 17/1/19 17/1/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

17 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
Descripción

ID.1

Tipo de datos

boolean

progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
Descripción

ID.2

Tipo de datos

boolean

patients scheduled for treatment with everolimus.
Descripción

ID.3

Tipo de datos

boolean

patients with at least one measurable lesion at baseline.
Descripción

ID.4

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
Descripción

ID.5

Tipo de datos

boolean

patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
Descripción

ID.6

Tipo de datos

boolean

patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
Descripción

ID.7

Tipo de datos

boolean

patients unwilling or unable to comply with the protocol.
Descripción

ID.8

Tipo de datos

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Descripción

ID.9

Tipo de datos

boolean

Similar models

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
boolean
ID.2
Item
progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
boolean
ID.3
Item
patients scheduled for treatment with everolimus.
boolean
ID.4
Item
patients with at least one measurable lesion at baseline.
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
boolean
ID.6
Item
patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
boolean
ID.7
Item
patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
boolean
ID.8
Item
patients unwilling or unable to comply with the protocol.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial